Capricor Therapeutics (NASDAQ:CAPR) Price Target Raised to $30.00

Capricor Therapeutics (NASDAQ:CAPR) had its target price increased by Cantor Fitzgerald from $25.00 to $30.00 in a research note issued to investors on Thursday morning,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock.

Several other research analysts also recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Capricor Therapeutics in a report on Wednesday, October 9th. Maxim Group increased their target price on Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Piper Sandler assumed coverage on Capricor Therapeutics in a report on Monday, October 21st. They set an “overweight” rating and a $35.00 price target on the stock. Finally, Oppenheimer reiterated an “outperform” rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a report on Monday, September 23rd. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. Based on data from MarketBeat, Capricor Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Trading Up 0.6 %

Shares of Capricor Therapeutics stock opened at $18.61 on Thursday. The firm’s 50 day moving average is $15.21 and its 200 day moving average is $8.48. The firm has a market capitalization of $845.08 million, a PE ratio of -17.56 and a beta of 4.00. Capricor Therapeutics has a 1 year low of $2.87 and a 1 year high of $23.40.

Insider Transactions at Capricor Therapeutics

In other news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the firm’s stock in a transaction dated Friday, September 20th. The stock was bought at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the transaction, the insider now directly owns 7,090,351 shares in the company, valued at $38,004,281.36. This represents a 65.21 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 12.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Capricor Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets bought a new position in shares of Capricor Therapeutics in the 1st quarter worth about $40,000. Main Street Financial Solutions LLC increased its holdings in Capricor Therapeutics by 37.5% in the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after purchasing an additional 7,500 shares in the last quarter. SG Americas Securities LLC acquired a new position in Capricor Therapeutics in the third quarter valued at approximately $133,000. Rhumbline Advisers bought a new position in shares of Capricor Therapeutics during the 2nd quarter worth approximately $147,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Capricor Therapeutics during the 3rd quarter worth approximately $161,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.